AbCellera Biologics Inc.
US ˙ NasdaqGS ˙ CA00288U1066

SecurityABCL / AbCellera Biologics Inc.
InstitutionXTX Topco Ltd
Latest Disclosed Ownership192,450 shares
Latest Disclosed Value $ 671,651
XTX Topco Ltd reports 47.02% decrease in ownership of ABCL / AbCellera Biologics Inc.

On May 15, 2026 - XTX Topco Ltd filed a 13F-HR form disclosing ownership of 192,450 shares of AbCellera Biologics Inc. (US:ABCL) valued at $671,650 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 363,251 shares of AbCellera Biologics Inc.. This represents a change in shares of -47.02% during the quarter. The current value of the position is $1,100,814 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ABCELLERA BIOLOGICS COM 00288U106 192,450 -170,801 -47.02 672 -45.97 0.0117
2026-02-17 2025-12-31 13F ABCELLERA BIOLOGICS COM 00288U106 363,251 363,251 1,242 0.0326
2025-11-14 2025-09-30 13F ABCELLERA BIOLOGICS COM 00288U106 0 -66,444 -100.00 0 -100.00
2025-08-12 2025-06-30 13F ABCELLERA BIOLOGICS COM 00288U106 66,444 21,191 46.83 228 127.00 0.0094
2025-05-08 2025-03-31 13F ABCELLERA BIOLOGICS COM 00288U106 45,253 -46,501 -50.68 101 -62.69 0.0052
2025-02-13 2024-12-31 13F ABCELLERA BIOLOGICS COM 00288U106 91,754 91,754 269 0.0221
2024-11-14 2024-09-30 13F ABCELLERA BIOLOGICS COM 00288U106 0 -33,590 -100.00 0 -100.00
2024-08-12 2024-06-30 13F ABCELLERA BIOLOGICS COM 00288U106 33,590 33,590 99 0.0085
2024-02-13 2023-12-31 13F ABCELLERA BIOLOGICS COM 00288U106 0 -44,331 -100.00 0 -100.00
2023-11-13 2023-09-30 13F ABCELLERA BIOLOGICS COM 00288U106 44,331 44,331 204 0.0348
2023-02-14 2022-12-31 13F ABCELLERA BIOLOGICS COM 00288U106 0 -68,657 -100.00 0 -100.00
2022-11-14 2022-09-30 13F ABCELLERA BIOLOGICS COM 00288U106 68,657 49,780 263.71 679 237.81 0.1681
2022-08-15 2022-06-30 13F ABCELLERA BIOLOGICS COM 00288U106 18,877 4,837 34.45 201 46.72 0.0821
2022-05-13 2022-03-31 13F ABCELLERA BIOLOGICS COM 00288U106 14,040 14,040 137 0.0601
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.